Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

AHS Cancer Control Alberta

Status: Completed

Conditions: Testicular Cancer; Non-seminomatous; Seminoma

Study type: Observational

Funder types: Other

Identifiers

NCT00705094

GU-24167

Details and patient eligibility

About

For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.

Full description

The aim of this pilot study is to examine global and regional LV systolic and diastolic function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.

Enrollment: 30 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• surgery and surveillance
• surgery and multi-cycle chemotherapy
• both good and intermediate prognosis seminoma and non-seminomatous germ cell testicular tumors
• Karnofsky performance index > 70%
• no contraindications to cardiopulmonary testing

Exclusion criteria

• documented cardiovascular disease or evidence of myocardial ischemia on the incremental exercise (VO2peak) test.

Trial design

30 participants in 2 patient groups

1

Description:

Testicular cancer patients who have received surgery and are scheduled for surveillance

2

Description:

Testicular cancer patients who have received surgery and are scheduled for chemotherapy